Holdings
Defiance Autism Impact ETF
As of Jun 30, 2026, Defiance Autism Impact ETF reported 38 positions worth US$1.35M. Largest: Definium Therapeutics, Inc., Neuren Pharmaceuticals Limited and Lifestance Health Group, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Definium Therapeutics, Inc. | 1,370 | US$64,445 | first report | Jun 30, 2026 |
| Neuren Pharmaceuticals Limited | 3,554 | US$43,704 | first report | Jun 30, 2026 |
| Lifestance Health Group, Inc. | 3,838 | US$41,105 | first report | Jun 30, 2026 |
| Otsuka Holdings Co., Ltd. | 600 | US$39,889 | first report | Jun 30, 2026 |
| Acadia Healthcare Company, Inc. | 1,328 | US$39,216 | first report | Jun 30, 2026 |
| Acadia Pharmaceuticals Inc. | 1,544 | US$39,063 | first report | Jun 30, 2026 |
| Maplight Therapeutics, Inc. | 1,088 | US$38,994 | first report | Jun 30, 2026 |
| Abbvie Inc. | 146 | US$36,739 | first report | Jun 30, 2026 |
| Brightspring Health Services, Inc. | 524 | US$36,544 | first report | Jun 30, 2026 |
| Revvity, Inc. | 326 | US$36,271 | first report | Jun 30, 2026 |